A life sciences construction project executive delivers a facility that must pass commissioning, qualification and validation before the owner can use it, so the construction record is part of the product. Screen for change control discipline and a commissioning track record, not for lab square footage. Adjacent experience transfers from healthcare and data center work; the validation mindset usually does not.
A life sciences construction project executive hands over a building that works perfectly, and the owner cannot use it for another five months.
Nothing is wrong with the building. The mechanical systems balance, the finishes are clean, the punch list is closed. What is missing is the evidence that the building was built the way the qualified drawings say it was, because three field changes were made in month nine and nobody ran them through change control. The validation team finds the gap. The owner’s launch date moves.
That gap is the whole seat. It is also the thing almost no brief for the role mentions, because it does not happen during construction. It happens afterward, to the person who thought they were finished.
What does a life sciences construction project executive deliver?
A validated facility, not a completed one. A life sciences construction project executive carries the design, procurement and construction of a laboratory, pilot plant or cGMP manufacturing suite through to the point where the owner’s quality function accepts it, which happens after substantial completion and depends on the construction record being complete and traceable.
That definition changes the job in three ways a commercial brief does not anticipate.
First, the drawings are controlled documents. On a cGMP suite regulated under 21 CFR Part 211, the owner has to demonstrate that the facility was designed, built and qualified to a documented standard. A field change to a duct route or a drain location that would be a red-line on a commercial job is, here, a deviation that has to be assessed for impact on the qualified design and recorded as such. The project executive owns that discipline on the contractor side.
Second, commissioning is not a closeout activity. Worker protection on the same systems runs under OSHA construction standards, and the chemical and biological exposure side is covered by NIOSH guidance that the commissioning plan has to respect. It is a program that starts in design, with a commissioning agent who has authority over sequence in a way commercial contractors find unfamiliar. Mechanical and electrical systems in a containment lab or a cleanroom suite are tested against acceptance criteria, and a system that fails is not handed over.
Third, the schedule has a phase after the contractor thinks it is done. Installation qualification and operational qualification run against the construction record, and a project executive who has not built the record cannot help the owner through them. The NIH design and CDC laboratory guidance both describe facility requirements that only make sense once that sequence is understood.
Which is why the pool of people who have done it is narrower than the pool of people who have built laboratories.
Why does adjacent experience transfer unevenly?
Because two of the three disciplines are common and the third is rare. Occupied-site discipline transfers from healthcare, commissioning rigor from data center work, and both pools produce capable candidates. The validation mindset, where an unrecorded field change can fail the facility months later, is specific to regulated life sciences and does not transfer.
Consider what each adjacent pool brings and lacks.
A healthcare construction executive has built inside a live operation with an infection control veto over their sequence, which is the right instinct for a lab renovation inside an occupied research building. What they may not have carried is a project where the paperwork was the product, because a hospital renovation is accepted on inspection rather than on qualification.
A data center project executive brings commissioning rigor and a tolerance for mechanical density that most commercial builders lack. Level 5 integrated systems testing is close cousin to operational qualification. What they may not have met is a regulator, or an owner’s quality unit, whose acceptance criteria are set by a federal code rather than by an uptime service level. A manufacturing project executive from process-plant work brings the owner-equipment discipline and usually the cGMP vocabulary too. The data center project executive piece sets out that seat’s own profile.
| Candidate background | Transfers directly | Usually missing |
|---|---|---|
| Healthcare construction | Live-operation phasing, containment | Qualification-driven documentation |
| Data center construction | Commissioning, mechanical density | Regulatory acceptance criteria |
| Pharmaceutical or cGMP | Change control, validation | Nothing structural; the pool is thin |
| Semiconductor or cleanroom | Environmental control, contamination | Biological containment logic |
| Commercial ground-up | Delivery scale, buyout | Almost everything above |
The right column is where the interview lives. A candidate from the healthcare or data center pool who can describe, unprompted, why a field change matters after handover has already made the transition in their head. One who describes it as a punch-list item has not.
Compensation tracks the BLS construction management bands at the top end, with a premium for the validation experience because it is scarce. The metropolitan area tables matter more than usual here: the life sciences clusters around Boston, the Research Triangle in North Carolina, and the growing Texas and Atlanta biomanufacturing markets compete directly for the same few hundred people.
Scarcity of that kind has a price, and it is easiest to see when the alternative is costed.
What does a validation failure cost?
Months of owner occupancy, not days of contractor schedule. A life sciences construction project executive who lets three field changes through without change control has created a gap in the evidence, and closing it means investigation, re-qualification and delay on the owner’s side. The contractor finished on time. The owner’s launch did not.
Put a number on the owner’s side, because that is where the cost lands and where the contractor’s reputation is decided.
A $90 million cGMP fill-finish suite is built to support a product launch. Three undocumented changes in the mechanical scope are found during operational qualification. Investigating them, assessing impact and re-qualifying the affected systems takes twenty weeks. The owner’s cost of a delayed launch is not the contractor’s to bear contractually, but the owner will remember who caused it, and biomanufacturing owners run programs for decades.
On the contractor’s own ledger, twenty weeks of extended support staff, re-testing and commissioning agent time on a suite of that size runs to roughly $700,000. Against that, the pay difference between a capable commercial executive at $210,000 and a proven life sciences executive at $250,000 is $40,000 a year.
The illustrative figures price only the contractor’s exposure. The owner’s cost, and the relationship consequence, are larger and do not appear on any job cost report. The general shape of that loss, one seat down, is worked through in the cost of a failed project manager hire.
The market makes the seat harder to fill than the arithmetic suggests. In the 2025 AGC and NCCER workforce survey, 91.7 percent of the 1,041 contractors answering the salaried-hiring question reported difficulty filling salaried positions, and the AGC release reports shortages delaying projects across the sector. The Census Bureau spending series shows manufacturing construction, which includes biomanufacturing, among the fastest-growing categories, so the demand for this seat is rising into a pool that was already thin. The ENR rankings show which contractors currently hold the large life sciences programs, which is where the experienced people sit.
Those contractors are not advertising when they lose one, and neither should you.
Can a life sciences project executive search be run publicly?
Rarely, and the reason is the client. A posting for a life sciences construction project executive tells the biomanufacturing owner that the person running its program is being replaced, and tells competitors pursuing that owner that the incumbent is exposed. A contractor entering the sector has the reverse problem: the posting announces the strategy.
Selah Talent Partners runs these as confidential executive search for mandates that cannot be publicly posted, which is a different process from a discreet version of a posted search. The mechanics are set out in how a confidential construction search runs, and the seated-incumbent case in confidential construction search.
Selah works with contractors and construction consultancies across the United States on preconstruction and estimating, project and construction management, and cost and commercial management. Candidates are never charged a fee at any stage.
This is not the seat for a contractor building a shell-and-core research office with lab-ready infrastructure and no regulated process inside it. There, a strong commercial or healthcare executive is fully adequate and the life sciences premium is waste. The seat earns its cost on cGMP, containment and pilot-plant work, where the facility has to pass a second test after the contractor has passed the first. The occupied-site version of the same problem, from the clinical side, is set out in hiring a healthcare construction operations director.
Build the record, not just the building
The instinct on this hire is to find someone who has built laboratories.
Laboratory square footage is the wrong measure. The seat is decided by whether the candidate has carried a facility through the test that happens after handover, and whether they understood, while the walls were open, that every unrecorded decision was a future finding. People who have done that once do not need to be told twice.
Ask every candidate about the field change that surfaced during qualification. Then listen for whether they describe a process or an apology.
If you are scoping this seat and want to compare notes on the brief, get in touch.
Sources and further reading
- 21 CFR Part 211 current good manufacturing practice for finished pharmaceuticals
- NIH research facility design guidance
- CDC laboratory safety and facility guidance
- BLS occupational data, construction managers
- BLS metropolitan area wage data by metro
- AGC release 2025 workforce survey findings
- Census Bureau construction spending by category
- ENR top 400 contractor rankings
- OSHA construction safety standards
- NIOSH occupational health research